glp 1 risks Gastrointestinal effect and adverse effects of GLP-1 receptor agonist Your guide to GLP-1 side

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has today approved a new indication for Wegovy (semaglutide) to reduce the risk of overweight and obese adults suffering serious heart problems or strokes.

Originally developed and positioned as treatments for type 2 diabetes, these agents are now equally associated with weight management, reshaping how clinicians, patients, and pharmacies understand metabolic disease

Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase depression risk, a new review concludes.

That means it needs strict temperature control, precise manufacturing, and no contamination

But despite widespread use of these drugs by perimenopausal women, research has largely ignored the unique risks and potential opportunities for optimizing health that GLP-1s may pose for this population.

Ease your GLP-1 journey with Side Effect Relief